Literature DB >> 6428014

The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis.

D J Girling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6428014     DOI： 10.1016/0041-3879(84)90024-2

Source DB:  PubMed          Journal:  Tubercle        ISSN： 0041-3879


× No keyword cloud information.
  13 in total

1.  The management of tuberculous meningitis.

Authors:  M Humphries
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

2.  Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis.

Authors:  G A Ellard; M J Humphries; M Gabriel; R Teoh
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-31

3.  Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used.

Authors:  Jotam G Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

4.  Antituberculous therapy in children.

Authors:  V Seth
Journal:  Indian J Pediatr       Date:  1986 Mar-Apr       Impact factor: 1.967

5.  Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Sheen; Miguel Quiliano; Andrés Gutierrez; Robert H Gilman
Journal:  Infect Genet Evol       Date:  2009-12-04       Impact factor: 3.342

Review 6.  Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens.

Authors:  Bjørn Blomberg; Bernard Fourie
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

Review 8.  Avoidance and management of adverse reactions to antituberculosis drugs.

Authors:  A M Patel; J McKeon
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

9.  Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery.

Authors:  Shelley E Haydel
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-01

10.  Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.

Authors:  Paolo Miotto; Andrea M Cabibbe; Silke Feuerriegel; Nicola Casali; Francis Drobniewski; Yulia Rodionova; Daiva Bakonyte; Petras Stakenas; Edita Pimkina; Ewa Augustynowicz-Kopeć; Massimo Degano; Alessandro Ambrosi; Sven Hoffner; Mikael Mansjö; Jim Werngren; Sabine Rüsch-Gerdes; Stefan Niemann; Daniela M Cirillo
Journal:  mBio       Date:  2014-10-21       Impact factor: 7.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.